v3.26.3
Segment Information
12 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information

16. Segment Information

The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is on discovering and developing small molecule drugs with an emphasis on viral infections and immunological diseases. The Company’s Chief Operating Decision Maker (“CODM”) is the Company’s Chief Executive Officer. The CODM reviews consolidated operating results and utilizes net loss from the Statement of Operations against budget forecasts as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by expense category and program. The CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis. Certain prior year program amounts have been reclassified for consistency with the current year presentation provided to the CODM. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s CODM. The CODM is regularly provided information on total cash, which is inclusive of cash, cash equivalents and marketable securities, as a measure of segment assets. As of September 30, 2026, the Company’s cash, cash equivalents and marketable securities were $194,513.

The following table presents selected financial information with respect to the Company’s single operating segment for the years ended September 30, 2026, 2025, and 2024 (in thousands):

 

 

Years Ended September 30,

 

 

 

2026

 

 

2025

 

 

2024

 

Revenue

 

 

 

 

 

 

 

 

 

Royalty revenue

 

$

63,001

 

 

$

65,324

 

 

$

67,635

 

Total revenue

 

 

63,001

 

 

 

65,324

 

 

 

67,635

 

Operating expenses:

 

 

 

 

 

 

 

 

 

RSV

 

 

25,898

 

 

 

59,808

 

 

 

86,367

 

Total virology

 

 

25,898

 

 

 

59,808

 

 

 

86,367

 

KIT

 

 

17,067

 

 

 

18,052

 

 

 

19,822

 

STAT6

 

 

25,543

 

 

 

16,614

 

 

 

4,691

 

MRGPRX2

 

 

12,393

 

 

 

9,114

 

 

 

6,525

 

Total immunology

 

 

55,003

 

 

 

43,780

 

 

 

31,038

 

Early discovery

 

 

6,869

 

 

 

2,214

 

 

 

8,471

 

Other pipeline programs

 

 

776

 

 

 

938

 

 

 

5,600

 

Total other programs

 

 

7,645

 

 

 

3,152

 

 

 

14,071

 

General and administrative

 

 

36,835

 

 

 

43,933

 

 

 

57,850

 

Total operating expenses

 

 

125,381

 

 

 

150,673

 

 

 

189,326

 

Loss from operations

 

 

(62,380

)

 

 

(85,349

)

 

 

(121,691

)

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(14,074

)

 

 

(7,681

)

 

 

(10,940

)

Interest and investment income, net

 

 

8,225

 

 

 

9,442

 

 

 

14,770

 

Change in fair value of Series 1 nonconvertible preferred stock

 

 

21

 

 

 

39

 

 

 

73

 

Total other income (expense), net

 

 

(5,828

)

 

 

1,800

 

 

 

3,903

 

Loss before income taxes

 

 

(68,208

)

 

 

(83,549

)

 

 

(117,788

)

Income tax benefit (expense)

 

 

(40

)

 

 

1,660

 

 

 

1,743

 

Net loss

 

$

(68,248

)

 

$

(81,889

)

 

$

(116,045

)